Oberweis Asset Management Inc. Buys 58,550 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Oberweis Asset Management Inc. raised its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 13.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 506,600 shares of the medical device company's stock after buying an additional 58,550 shares during the period. Oberweis Asset Management Inc. owned about 0.77% of Tandem Diabetes Care worth $18,248,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. AlphaQuest LLC grew its stake in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after buying an additional 748 shares during the last quarter. Assetmark Inc. grew its stake in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after buying an additional 535 shares in the last quarter. McIlrath & Eck LLC acquired a new position in Tandem Diabetes Care in the third quarter worth approximately $52,000. Finally, Smartleaf Asset Management LLC raised its position in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares in the last quarter.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded up $0.39 on Friday, hitting $18.06. 1,156,715 shares of the company were exchanged, compared to its average volume of 1,504,902. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company's 50 day moving average price is $20.17 and its two-hundred day moving average price is $29.22. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -9.36 and a beta of 1.52.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.90% of the company's stock.

Analyst Ratings Changes

TNDM has been the subject of several recent research reports. Mizuho started coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. Robert W. Baird lowered their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Sanford C. Bernstein cut Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Royal Bank of Canada reduced their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.